{"nctId":"NCT01162239","briefTitle":"Maintaining Nonsmoking","startDateStruct":{"date":"2010-05","type":"ACTUAL"},"conditions":["Nicotine Dependence"],"count":216,"armGroups":[{"label":"Extended Brief Contact","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline","Behavioral: Initial Individual counseling","Behavioral: Check-ins with medical staff"]},{"label":"Extended Health Education","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline","Behavioral: Initial Individual counseling","Behavioral: Extended Individual Counseling - Health Model"]},{"label":"Extended Relapse Prevention plus varenicline","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline","Behavioral: Initial Individual counseling","Behavioral: Extended Individual Counseling - Relapse Prevention Model"]},{"label":"Extended Relapse Prevention","type":"EXPERIMENTAL","interventionNames":["Drug: Varenicline","Behavioral: Initial Individual counseling","Behavioral: Extended Individual Counseling - Relapse Prevention Model"]}],"interventions":[{"name":"Varenicline","otherNames":["Chantix"]},{"name":"Initial Individual counseling","otherNames":[]},{"name":"Check-ins with medical staff","otherNames":[]},{"name":"Extended Individual Counseling - Health Model","otherNames":[]},{"name":"Extended Individual Counseling - Relapse Prevention Model","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years of age\n* Must be smoking 5 or more cigarettes per day\n\nExclusion Criteria:\n\n* Previous history of bipolar/manic-depressive disorder\n* Current diagnosis of schizophrenia\n* Acute life threatening diseases\n* Evidence of alcohol or other drug abuse so severe that the patient is judged to be potentially unable to comply with the protocol\n* Pregnancy or lactation\n* Individuals with out of normal range blood pressure, active angina, valve disease, valve replacement, active cardiomyopathies, myocardial infarction or Coronary artery bypass grafting (CABG) within one year, and Congestive heart failure (CHF)","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12","description":"Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) \\< 8 parts per million (ppm)) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"29","spread":null},{"groupId":"OG003","value":"20","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 24","description":"Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) \\< 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 52","description":"Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) \\< 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 64","description":"Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) \\< 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 104","description":"Point prevalent abstinence is defined as biochemically verified (confirmed carbon dioxide (CO) \\< 8 ppm) self-reported abstinence from smoking cigarettes in the past 7 days. Smoking status was then categorized as either Abstinent or Not Abstinent.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"16","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Combined Extended vs Brief Treatment at Week 24","description":"The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of Combined Extended vs Brief Treatment at Week 52","description":"The three extended treatment programs were combined and compared to the Brief treatment, with extended treatments expected to produce significant higher CO corrected abstinence rates overall. Comparisons will be tested using Chi-Square analysis.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":55},"commonTop":[]}}}